Login / Signup

Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study.

Tyng-Yuang JangPo-Cheng LiangDae Won JunJang Han JungHidenori ToyodaChih-Wen WangMan-Fung YuenKa Shing CheungSatoshi YasudaSung Eun KimEileen L YoonJihyun AnMasaru EnomotoRitsuzo KozukaMakoto ChumaAkito NozakiToru IshikawaTsunamasa WatanabeMasanori AtsukawaTaeang AraiKorenobu HayamaMasatoshi IshigamiYong Kyun ChoEiichi OgawaHyoung Su KimJae-Jun ShimHaruki UojimaSoung Won JeongSang Bong AhnKoichi TakaguchiTomonori SenohMaria ButiElena Vargas-Accarino IHiroshi AbeHirokazu TakahashiKaori InoueMing-Lun YehChia-Yen DaiJee-Fu HuangChung-Feng HuangWan-Long ChuangMindie H NguyenMing-Lung Yu
Published in: Journal of gastroenterology and hepatology (2024)
Long-term outcomes of all-cause mortality and liver-related and non-liver-related mortality did not differ between patients treated with ETV and those receiving TDF.
Keyphrases
  • cardiovascular events
  • hepatitis b virus
  • risk factors
  • acute lymphoblastic leukemia
  • cardiovascular disease
  • antiretroviral therapy
  • liver fibrosis